Gui-Bin Qiao
Overview
Explore the profile of Gui-Bin Qiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang J, Huang S, Chen Q, Wu H, Qiao G
World J Gastrointest Surg
. 2024 Jul;
16(6):1537-1547.
PMID: 38983355
Background: The optimal extent of lymphadenectomy in esophageal squamous cell carcinoma (ESCC) patients remained debatable. Aim: To explore the ideal number of cleared lymph nodes in ESCC patients undergoing upfront...
2.
Chen R, Xu S, Deng M, Hao S, Chen J, Ma X, et al.
Signal Transduct Target Ther
. 2024 Apr;
9(1):80.
PMID: 38565536
RNA-binding proteins (RBPs)-RNA networks have contributed to cancer development. Circular RNAs (circRNAs) are considered as protein recruiters; nevertheless, the patterns of circRNA-protein interactions in colorectal cancer (CRC) are still lacking....
3.
Liu S, Dong S, Yang X, Liao R, Jiang B, Wang Q, et al.
Signal Transduct Target Ther
. 2023 Dec;
8(1):442.
PMID: 38057314
This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab-chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stage IIA-IIIB (AJCC...
4.
Zhong W, Yan H, Chen K, Chen C, Gu C, Wang J, et al.
Signal Transduct Target Ther
. 2023 Feb;
8(1):76.
PMID: 36823150
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer (NSCLC) (NCT01407822). Herein,...
5.
Hu R, Zhang W, Li L, Zuo Z, Ma M, Ma J, et al.
Cell Death Dis
. 2021 Oct;
12(11):1023.
PMID: 34716308
Activation of adipose tissue macrophages (ATMs) contributes to chronic inflammation and insulin resistance in obesity. However, the transcriptional regulatory machinery involved in ATM activation during the development of obesity is...
6.
Guo L, Zhang M, Zhang H, Zhou J, Cai X, Long Y, et al.
Front Oncol
. 2020 Oct;
10:1568.
PMID: 33042801
This study investigated survival in selected Chinese patients with advanced lung adenocarcinoma who received initial chemotherapy with pemetrexed. We also explored the relationship between genetic biomarkers and pemetrexed efficacy. We...
7.
Zhou H, Zheng S, Li A, Gao Q, Ou Q, Chen Y, et al.
EClinicalMedicine
. 2020 Jul;
24:100422.
PMID: 32637899
Background: The efficacy and safety of neoadjuvant treatment over surgery alone and that of neoadjuvant chemoradiotherapy (NCRT) over neoadjuvant chemotherapy (NCT) in resectable esophageal carcinoma remains inconclusive. This study (NewEC)...
8.
Zhong W, Chen K, Chen C, Gu C, Wang J, Yang X, et al.
J Clin Oncol
. 2019 Jun;
37(25):2235-2245.
PMID: 31194613
Purpose: To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced mutation-positive non-small-cell lung cancer. Patients And Methods: This was a...
9.
Zhou Z, Chen G, Deng C, Tang J, Xie L, Zhou H, et al.
Cell Biol Int
. 2019 May;
43(12):1416-1424.
PMID: 31141247
Transcription factor 19 (TCF19) harbors a forkhead association (FHA) domain, a proline-rich region, a PHD or RING finger region, suggesting that TCF19 possesses a powerful function. However, its expression and...
10.
Wu Y, Wang C, Liao M, Guan Z, Gao C, Lu S, et al.
Transl Lung Cancer Res
. 2018 Jul;
7(3):428-436.
PMID: 30050780
The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not...